DNA条形码
抗药性
生物
癌症
条形码
计算生物学
抗性(生态学)
生物信息学
进化生物学
遗传学
计算机科学
操作系统
生态学
作者
Hyo-Eun Carrie Bhang,David A. Ruddy,Viveksagar Krishnamurthy Radhakrishna,Justina X. Caushi,Rui Zhao,Matthew M. Hims,Angad Singh,Iris Kao,Daniel P. Rakiec,Pamela Shaw,Marissa N. Balak,Alina Raza,Elizabeth Ackley,Nicholas Keen,Michael R. Schlabach,Michael Palmer,Rebecca J. Leary,Derek Y. Chiang,William R. Sellers,Franziska Michor
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2015-04-07
卷期号:21 (5): 440-448
被引量:515
摘要
Resistance to cancer therapies presents a significant clinical challenge. Recent studies have revealed intratumoral heterogeneity as a source of therapeutic resistance. However, it is unclear whether resistance is driven predominantly by pre-existing or de novo alterations, in part because of the resolution limits of next-generation sequencing. To address this, we developed a high-complexity barcode library, ClonTracer, which enables the high-resolution tracking of more than 1 million cancer cells under drug treatment. In two clinically relevant models, ClonTracer studies showed that the majority of resistant clones were part of small, pre-existing subpopulations that selectively escaped under therapeutic challenge. Moreover, the ClonTracer approach enabled quantitative assessment of the ability of combination treatments to suppress resistant clones. These findings suggest that resistant clones are present before treatment, which would make up-front therapeutic combinations that target non-overlapping resistance a preferred approach. Thus, ClonTracer barcoding may be a valuable tool for optimizing therapeutic regimens with the goal of curative combination therapies for cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI